COMMON STOCK |
12 Months Ended |
|---|---|
Dec. 31, 2025 | |
| Equity [Abstract] | |
| COMMON STOCK | NOTE 5 - COMMON STOCK During the year ended December 31, 2025, pursuant to the terms of the Merger with Nika BioTechnology, Inc (Note 1), the Company issued shares of common stock of the shares to be issued. During the year ended December 31, 2025, upon reconciliation of the DTC FAST balance transferred from Nika BioTechnology, Inc. pursuant to the Agreement and Plan of Merger dated February 12, 2024, the Transfer Agent of the Company identified and recorded 7,713,223 shares of common stock that had been reflected in the DTC system effective March 21, 2024, but had not been recorded in the Company's shareholder records. These shares were recorded in the Company's transaction journal and shareholder list during the year ended December 31, 2025 to reflect the appropriate balance as of the appropriate date. During the year ended December 31, 2025, pursuant to the terms of the Merger with Nika BioTechnology, Inc (Note 1), the Company issued 17,961,501 shares of common stock of the 204,205,027 shares to be issued. As of December 31, 2025, the total shares of common stock issued pursuant to the terms of the Merger with Nika BioTechnology, Inc. (Note 1) is 171,259,224 shares of common stock out of 204,205,027 to be issued. On October 31, 2025, pursuant to a Services Agreement with AJO Capital Inc., the Company issued 200,000 shares of common stock as consideration for services outlined in the agreement. |